Subscribe to RSS
DOI: 10.1055/s-0041-1726043
CD133, a Progenitor Cell Marker, is Reduced in Nasal Polyposis and Showed Significant Correlations with TGF-β1 and IL-8
Abstract
Introduction Combination of chronic inflammation and an altered tissue remodeling process are involved in the development of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). Studies demonstrated that mesenchymal stem cells expressing the progenitor gene CD133 were involved in a significant reduction of the chronic inflammatory process in the polypoid tissue.
Objective To evaluate the levels of CD133 (Prominin-1) in nasal polypoid tissue and its correlation with interleukin-8 (IL-8) and transforming growth factor β1 (TGF-β1).
Methods A total of 74 subjects were divided in the following groups: control group (n = 35); chronic rhinosinusitis with nasal polyps nonpresenting comorbid asthma and aspirin intolerance (CRSwNPnonAI) group (n = 27); and chronic rhinosinusitis with nasal polyps presenting comorbid asthma and aspirin intolerance (CRSwNPAI) group (n = 12). Histologic analysis and also evaluation of the concentration of CD133, IL-8, and TGF-β1 by enzyme-linked immunosorbent assay (ELISA) kits were performed in nasal tissue obtained from nasal polypectomy or from middle turbinate tissue.
Results Higher eosinophilic infiltration was found in both CRSwNP groups by histologic analysis. Lower levels of TGF-β1 and IL-8 were observed in both CRSwNP groups when compared with the control group, whereas the CD133 levels were significantly reduced only in the CRSwNPnonAI group compared with the control group.
Conclusion It was demonstrated that the nasal mucosa presenting polyposis showed a significant reduction of CD133 levels, and also that this reduction was significantly correlated with the reduction of TGF-β1 levels, but not with IL-8 levels. Therefore, these findings may be involved in the altered inflammatory and remodeling processes observed in the nasal polyposis.
Keywords
nose diseases - nasal polyps - aspirin-induced asthma - AC133 antigen - transforming growth factor β1 - interleukin-8* These authors contributed equally to the present work.
Publication History
Received: 26 April 2020
Accepted: 30 November 2020
Article published online:
25 June 2021
© 2021. Fundação Otorrinolaringologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
References
- 1 Hulse KE, Stevens WW, Tan BK, Schleimer RP. Pathogenesis of nasal polyposis. Clin Exp Allergy 2015; 45 (02) 328-346 DOI: 10.1111/cea.12472.
- 2 Fokkens WJ, Lund VJ, Hopkins C. et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology 2020; 58 (Suppl S29): 1-464 DOI: 10.4193/Rhin20.600.
- 3 Nakayama T, Sugimoto N, Okada N. et al. JESREC score and mucosal eosinophilia can predict endotypes of chronic rhinosinusitis with nasal polyps. Auris Nasus Larynx 2019; 46 (03) 374-383 DOI: 10.1016/j.anl.2018.09.004.
- 4 Cho S-W, Kim DW, Kim J-W, Lee CH, Rhee CS. Classification of chronic rhinosinusitis according to a nasal polyp and tissue eosinophilia: limitation of current classification system for Asian population. Asia Pac Allergy 2017; 7 (03) 121-130
- 5 Tokunaga T, Sakashita M, Haruna T. et al. Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study. Allergy 2015; 70 (08) 995-1003 DOI: 10.1111/all.12644.
- 6 Fokkens WJ, Lund VJ, Mullol J. et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012; 50 (01) 1-12
- 7 Pezato R, Voegels RL, Pinto Bezerra TF, Perez-Novo C, Stamm AC, Gregorio LC. Mechanical disfunction in the mucosal oedema formation of patients with nasal polyps. Rhinology 2014; 52 (02) 162-166 DOI: 10.4193/Rhin13.066.
- 8 Pezato R, Balsalobre L, Lima M. et al. Convergence of two major pathophysiologic mechanisms in nasal polyposis: immune response to Staphylococcus aureus and airway remodeling. J Otolaryngol Head Neck Surg 2013; 42: 27-27 DOI: 10.1186/1916-0216-42-27.
- 9 Stevens WW, Lee RJ, Schleimer RP, Cohen NA. Chronic rhinosinusitis pathogenesis. J Allergy Clin Immunol 2015; 136 (06) 1442-1453 DOI: 10.1016/j.jaci.2015.10.009.
- 10 DeConde AS, Mace JC, Levy JM, Rudmik L, Alt JA, Smith TL. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope 2017; 127 (03) 550-555 DOI: 10.1002/lary.26391.
- 11 Brescia G, Zanotti C, Parrino D, Barion U, Marioni G. Nasal polyposis pathophysiology: Endotype and phenotype open issues. Am J Otolaryngol 2018; 39 (04) 441-444 DOI: 10.1016/j.amjoto.2018.03.020.
- 12 Gregório L, Pezato R, Felici RS, Kosugi EM. Fibrotic Tissue and Middle Turbinate Exhibit Similar Mechanical Properties. Is Fibrosis a Solution in Nasal Polyposis?. Int Arch Otorhinolaryngol 2017; 21 (02) 122-125 DOI: 10.1055/s-0036-1593728.
- 13 Balsalobre L, Pezato R, Mangussi-Gomes J. et al. What is the Impact of Positive Airway Pressure in Nasal Polyposis? An Experimental Study. Int Arch Otorhinolaryngol 2019; 23 (02) 147-151 DOI: 10.1055/s-0038-1676095.
- 14 Pezato R, de Almeida DC, Bezerra TF. et al. Immunoregulatory effects of bone marrow-derived mesenchymal stem cells in the nasal polyp microenvironment. Mediators Inflamm 2014; 2014: 583409 DOI: 10.1155/2014/583409.
- 15 Pezato R, Gregorio L, Voegels R. et al. Hypotheses about the Potential Role of Mesenchymal Stem Cell on Nasal Polyposis: A Soft Inflamed Tissue Suffering from Mechanical Dysfunction. Austin Immunology 2016: 1
- 16 de Oliveira PWB, Pezato R, Agudelo JSH. et al. Nasal Polyp-Derived Mesenchymal Stromal Cells Exhibit Lack of Immune-Associated Molecules and High Levels of Stem/Progenitor Cells Markers. Front Immunol 2017; 8: 39 DOI: 10.3389/fimmu.2017.00039.
- 17 Miraglia S, Godfrey W, Yin AH. et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997; 90 (12) 5013-5021 DOI: 10.1182/blood.V90.12.5013.
- 18 Li Z. CD133: a stem cell biomarker and beyond. Exp Hematol Oncol 2013; 2 (01) 17-17 DOI: 10.1186/2162-3619-2-17.
- 19 You H, Ding W, Rountree CB. Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-β. Hepatology 2010; 51 (05) 1635-1644 DOI: 10.1002/hep.23544.
- 20 Takenobu H, Shimozato O, Nakamura T. et al. CD133 suppresses neuroblastoma cell differentiation via signal pathway modification. Oncogene 2011; 30 (01) 97-105 DOI: 10.1038/onc.2010.383.
- 21 Beier D, Hau P, Proescholdt M. et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007; 67 (09) 4010-4015 DOI: 10.1158/0008-5472.can-06-4180.
- 22 Nadal R, Ortega FG, Salido M. et al. CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy. Int J Cancer 2013; 133 (10) 2398-2407 DOI: 10.1002/ijc.28263.
- 23 Koennecke M, Böscke R, Pfannerstill A-C. et al. Neuronal Differentiation Capability of Nasal Polyps of Chronic Rhinosinusitis. Arch Immunol Ther Exp (Warsz) 2017; 65 (05) 431-443 DOI: 10.1007/s00005-017-0456-8.
- 24 Ma N, Ladilov Y, Moebius JM. et al. Intramyocardial delivery of human CD133+ cells in a SCID mouse cryoinjury model: Bone marrow vs. cord blood-derived cells. Cardiovasc Res 2006; 71 (01) 158-169 DOI: 10.1016/j.cardiores.2006.03.020.
- 25 Colombo A, Castellani M, Piccaluga E. et al. Myocardial blood flow and infarct size after CD133+ cell injection in large myocardial infarction with good recanalization and poor reperfusion: results from a randomized controlled trial. J Cardiovasc Med (Hagerstown) 2011; 12 (04) 239-248 DOI: 10.2459/JCM.0b013e328343d708.
- 26 Andreone P, Catani L, Margini C. et al. Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: A phase I clinical trial. Dig Liver Dis 2015; 47 (12) 1059-1066 DOI: 10.1016/j.dld.2015.08.018.
- 27 Tang KH, Ma S, Lee TK. et al. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology 2012; 55 (03) 807-820 DOI: 10.1002/hep.24739.
- 28 Association WM. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310 (20) 2191-2194 DOI: 10.1001/jama.2013.281053.
- 29 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254 DOI: 10.1016/0003-2697(76)90527-3.
- 30 Aghajani M, Mansoori B, Mohammadi A, Asadzadeh Z, Baradaran B. New emerging roles of CD133 in cancer stem cell: Signaling pathway and miRNA regulation. J Cell Physiol 2019; 234 (12) 21642-21661 DOI: 10.1002/jcp.28824.
- 31 Ko SBH, Mizuno N, Yatabe Y. et al. Corticosteroids correct aberrant CFTR localization in the duct and regenerate acinar cells in autoimmune pancreatitis. Gastroenterology 2010; 138 (05) 1988-1996 DOI: 10.1053/j.gastro.2010.01.001.
- 32 Shidal C, Singh NP, Nagarkatti P, Nagarkatti M. MicroRNA-92 Expression in CD133+ Melanoma Stem Cells Regulates Immunosuppression in the Tumor Microenvironment via Integrin-Dependent Activation of TGFβ. Cancer Res 2019; 79 (14) 3622-3635 DOI: 10.1158/0008-5472.can-18-2659.
- 33 Hu B, Li G, Ye Z. et al. Transcription factor networks in aged naïve CD4 T cells bias lineage differentiation. Aging Cell 2019; 18 (04) e12957 DOI: 10.1111/acel.12957.
- 34 Xue G, Jin G, Fang J, Lu Y. IL-4 together with IL-1β induces antitumor Th9 cell differentiation in the absence of TGF-β signaling. Nat Commun 2019; 10 (01) 1376 DOI: 10.1038/s41467-019-09401-9.
- 35 Ilnicka A, Gocek E, Łopatecka J, Marcinkowska E. Regulation of FOXP3 expression in myeloid cells in response to all-trans-retinoic acid, interleukin 2 and transforming growth factor β. Dev Comp Immunol 2019; 96: 18-26 DOI: 10.1016/j.dci.2019.02.019.
- 36 Zhang S. The role of transforming growth factor β in T helper 17 differentiation. Immunology 2018; 155 (01) 24-35 DOI: 10.1111/imm.12938.
- 37 Smith KA, Pulsipher A, Gabrielsen DA, Alt JA. Biologics in Chronic Rhinosinusitis: An Update and Thoughts for Future Directions. Am J Rhinol Allergy 2018; 32 (05) 412-423 DOI: 10.1177/1945892418787132.
- 38 Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 2001; 12 (04) 375-391 DOI: 10.1016/S1359-6101(01)00016-8.
- 39 Bachi ALL, Rios FJO, Vaisberg PHC. et al. Neuro-immuno-endocrine modulation in marathon runners. Neuroimmunomodulation 2015; 22 (03) 196-202
- 40 Kim JA, Cho JH, Park I-H, Shin JM, Lee SA, Lee HM. Diesel Exhaust Particles Upregulate Interleukins IL-6 and IL-8 in Nasal Fibroblasts. PLoS One 2016; 11 (06) e0157058 DOI: 10.1371/journal.pone.0157058.
- 41 Barzegar Behrooz A, Syahir A, Ahmad S. CD133: beyond a cancer stem cell biomarker. J Drug Target 2019; 27 (03) 257-269 DOI: 10.1080/1061186X.2018.1479756.